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Objective. This study was performed to analyze the associations between cervical human papillomavirus (HPV) infection and
human immunodeﬁciency virus (HIV) acquisition, using cervical samples from previous studies in Tanzania and Uganda.
Methods. A total of 161 adult women who acquired HIV infection during follow-up and 464 individually matched HIV-sero-
negative controls were selected from 5 cohorts of women working in bars and recreational facilities. Stored cervical samples were
tested for 37 HPV genotypes, using a polymerase chain reaction assay (Roche Linear Array genotyping assay). Multivariate matched
analysis using conditional logistic regression was performed to evaluate HPV infection, persistence, and clearance as predictors of
HIV acquisition.
Results. HIV seroconverters were signiﬁcantly more likely than controls to frequently drink alcohol and to be infected with
Chlamydia trachomatis, Neisseria gonorrhoeae, or herpes simplex virus type 2. There was no evidence of an association between
HIV acquisition and any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% conﬁdence interval,
.66–1.57) or between HIV acquisition and persistent HPV infection (deﬁned as 2 positive HPV genotype–speciﬁc test results at least
6 months apart), cleared HPV infection (deﬁned as a positive HPV test result followed by negative HPV genotype–speciﬁc test re-
sult), or newly acquired HPV infection, compared with HPV-negative women.
Conclusions. There was no evidence of association between HPV infection status and subsequent HIV acquisition. These results
stand in contrast to other observational studies.
Keywords. human papillomavirus; HIV (transmission, prevention); Sub-Saharan Africa.
Human papillomavirus (HPV) is a highly prevalent sexually
transmitted virus. There are 40 genotypes that infect the genital
mucosa [1], 13 of which are regarded as carcinogenic [2]. Per-
sistent infection with carcinogenic HPV (ie, high-risk HPV
[HR-HPV]) genotypes is the cause of almost all cases of cervical
cancer [3], the third most common cancer among women
worldwide [4].HPV DNA has also been associated with cancer-
ous lesions of the vagina, vulva, penis, anus, and oropharynx [3,
5]. Bivalent (Cervarix; covering HPV 16 and 18) and quadriva-
lent (Gardasil; covering HPV 6, 11, 16, and 18) HPV vaccines
are available. A nonavalent vaccine (covering HPV 6, 11, 16, 18,
31, 33, 45, 52, and 58) gained Food and Drug Administration
approval in December 2014 [6]. More than 80% of men and
women contract HPV at least once in their lifetime [3, 7]. How-
ever, only a small proportion of these infections persist to cause
lesions, which can progress to cancer [8, 9], and 90% of infec-
tions are cleared within 2 years [10].
East African women harbor the highest HPV DNA pre-
valence in the world (31.7%; 95% conﬁdence interval [CI],
29.5–33.8) and experience the highest age-standardized inci-
dence rate of cervical cancer (42.7 cases/100 000 women/year)
[4, 11–13]. Among cytologically normal, human immunodeﬁ-
ciency virus (HIV)–negative, young women with a median
age of 18 years, 73.5% in Tanzania [14] and 73.2% in Uganda
[15] were found to have detectable HPV DNA of any genotype.
Detection of HPV DNA increases rapidly after HIV seroconver-
sion in HIV-infected women, compared with detection rates
over time in women who remain HIV uninfected [16, 17].
HPV is more likely to persist and to progress to cancer in
HIV-positive and immunosuppressed women [18, 19].
There is growing evidence that HPVmay be an important co-
factor in HIV acquisition. There is a plausible biological mech-
anism for this association: weakened cell adhesion caused by
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HPV infection could expose basal layers of the epithelium in the
genital tract and form additional HIV entry points [20, 21].
HPV infection and the mechanisms involved in its clearance
may cause an inﬂux of inﬂammatory cytokines [21], macro-
phages, and T cells [22], creating a favorable environment for
HIV invasion. A meta-analysis found an association between
detectable HPV DNA and HIV acquisition in 7 of 8 observa-
tional studies of both men and women [23, 24–29]; there was
a 2-fold increased risk of HIV acquisition among women with
prevalent HPV infection with any HPV genotype (hazard ratio,
2.06; 95% CI, 1.44–2.94). Similar associations were observed for
infection with HR HPV and low-risk HPV (LR-HPV) geno-
types and in 2 studies analyzing the clearance of any genotype
[27, 28], but no association was found with HPV persistence.
Since this meta-analysis, 2 further observational studies in
South Africa that investigated cervical samples conﬁrmed the
association between any HPV infection and HIV acquisition
in women [30, 31]. Two studies involving men have shown a
positive association between penile HPV clearance and HIV ac-
quisition [32, 33]. Clearance of penile HPV infections was asso-
ciated with elevated dendritic cell density in the foreskin
epidermis [33].
In this article, we present ﬁndings from a nested case-control
study undertaken to investigate the association between cervical
HPV infection and HIV acquisition, using stored cervical sam-
ples from 5 previous studies in the Lake Zone and Kilimanjaro
regions of Tanzania (4 studies) and Kampala, Uganda (1 study).
The extent to which HPV infection, persistence, and clearance
appear to be predictors for HIV infection is described.
METHODS
Study Participants and Design
Cases (women who acquired HIV infection after enrollment)
and controls (women who remained HIV negative) were select-
ed from 5 previously enrolled cohorts of women aged 16–45
years working in bars, guesthouses, and recreational facilities
in urban and semiurban areas of Tanzania and Uganda
(Table 1). Recruitment methods for these studies have been de-
scribed previously [34–37]. All studies recruited women from
their place of work, followed them for ≥12 months between
2002 and 2011, and measured the incidence of HIV infection
and other sexually transmitted infections (STIs) at 3–6-month
intervals. There was good retention of participants at 12 months
across all studies (range, 68% [36] to 90% [37]). Participants
were interviewed at enrollment and follow-up visits on socioe-
conomic status, education level, alcohol and drug usage, sexual
behavior, and family-planning practices.
Across the 5 studies, 178 women were HIV negative at enroll-
ment and seroconverted to HIV during follow-up; of these, 172
attended at least 1 study visit ≤12 months before the ﬁrst detec-
tion of HIV and were selected as cases. Cases were individually
matched with 3 randomly selected controls from the same study
who attended the same follow-up visits but remained HIV sero-
negative at the time points selected and at the ﬁrst visit after the
visits selected for analysis. Controls could become HIV seropos-
itive at a later visit. Of the 688 women from the original sample
selection list, 664 (166 cases and 498 controls [96.5%]) contrib-
uted stored samples for testing; samples from 6 cases could not
be located in the laboratory archives. If control samples were
missing, substitute controls were selected. Some HPV test
Table 1. Summary of 5 Cohort Studies From East Africa That Were Used for the Nested Case-Control Study of the Association Between Human
Papillomavirus Infection and Human Immunodeficiency Virus (HIV) Acquisition
Study (Location) Population
HIV-Negative
Enrollees, No. Period
Follow-up
Duration, mo
Relevant
Sample Types
Sample Collection
Frequency
Cases
(n = 161)
Controls
(n = 464)
HSV2 Suppressive
Treatment Trial
(Lake Zone,
Tanzania)
Women working in
settings such as bars
and guesthouses; age
16–35 y
821 2003–2007 30 Blood, vaginal
swab,
cervical
swab, CVL
Blood: every 3 mo;
cervical-vaginal: 0,
6, 12, 24, 30 mo
54 154
Microbicide
Feasibility Cohort
(Lake Zone)
Women working in
settings such as bars
and guesthouses; age
16–54 y
1156 2002–2004 12 Blood, vaginal
swab,
cervical
swab
0, 6, 12 mo (and at 3
and 9 mo for those
with symptoms of
HIV infection/STIs)
19 56
Women’s Health
Project (Lake
Zone)
Women working in
settings such as bars
and guesthouses; age
18–44 y
966 2008–2009 12 Blood, vaginal
swab,
cervical
swab, CVL
Blood: 0, 3, 6, 9, 12;
cervical-vaginal:
0, 6, 12 mo
28 82
EDCTP Vaccine
Cohort
(Kilimanjaro
Region, Tanzania)
Women working in
settings such as bars
and guesthouses; age
18–44 y
412 2009–2011 12 Blood, vaginal
swab,
cervical
swab
0, 3, 6, 9, 12 mo 14 39
Good Health for
Women,
(Kampala,
Uganda)
Self-reported female sex
workers and women
working in
entertainment; age
≥18 y
646 2008–2011 18 Blood, vaginal
swab,
cervical
swab
0, 3, 6, 9, 12, 18 mo
(blood was also
collected at 15 mo)
46 133
Abbreviations: CVL, cervico-vaginal lavage; STI, sexually transmitted infection.
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results were invalid; therefore, the ﬁnal sample size comprised
161 cases and 464 controls.
Ethics approval for the 4 studies in Tanzania had been granted
by the Medical Research Coordinating Committee of Tanzania.
The Ugandan study had received approval from the Science
and Ethics Committee of the Ugandan Virus Research Institute
and the Uganda National Committee for Science and Technolo-
gy. All 5 studies were approved by the ethics committee of the
London School of Hygiene and Tropical Medicine. All partici-
pants provided consent for the storage and potential further anal-
ysis of their information and samples.
Laboratory Methods
None of the studies had previously tested samples for HPV.
Cervical samples from study visits before HIV seroconversion
and when HIV was ﬁrst detected, as well as those from the
equivalent visits in controls, were tested for detectable HPV
DNA, using the Linear Array HPV genotyping assay (Roche,
Pleasanton, California) [38]. This test detects 13 HR-HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68)
and 24 LR-HPV types (6, 11, 26, 40, 42, 53, 54, 55 [also
known as 44], 61, 62, 64 [also known as 34], 66, 67, 69, 70,
71, 72, 73, 81, 82, IS39, 83, 84, and CP6108 [also known as
89]) [4]. As IS39 is regarded as a subtype of HPV 82, these ge-
notype-speciﬁc results were combined during analysis into just
1 variable for HPV 82 [1]. Cervical samples were either extracts
of buffer in which cervical swabs were washed (4 studies) or a
supernatant aliquot from a cervico-vaginal lavage (CVL) speci-
men (1 study), depending on the availability of stored samples.
HPV genotyping was performed in the laboratory of the Na-
tional Institute for Medical Research (NIMR), Mwanza, accord-
ing to the manufacturer’s instructions. External quality
assurance was performed by the Catalan Institute of Oncology
(ICO), Barcelona, Spain. A random selection of 102 samples
(5%) was tested by both laboratories. There was good agreement
in the detection of any HPV (κ = 0.69; Supplementary Table 1).
Data on HIV infection and STIs were obtained from the orig-
inal study databases. All studies used >1 test for conﬁrmation of
HIV results. The HSV-2 Suppressive Treatment Trial performed
parallel enzyme-linked immunosorbent assays (ELISAs; Vironos-
ticka Uni-Form II Ag/Ab [bioMerieux, Marcy l'Etoile, France]
and Murex HIVAg/Ab Combination [Murex Biotech, Dartford,
UK]). If results were discordant or indeterminate, HIV-1 p24
antigen enzyme immunoassay (EIA; Biorad Genetic Systems,
Hemel Hempstead, UK) was used to detect acute infection. A
negative or indeterminate result with the p24 antigen EIA was
conﬁrmed by Western blot [34]. The Microbicide Feasibility
Study used sequential testing on a gelatin-particle agglutination
test (Serodia HIV-1/2; Fujirebio, Tokyo, Japan), followed by a
conﬁrmatory ELISA (Vironosticka Uni-Form II) [36]. For both
theMwanzaWomen’s Health cohort and theMoshi Vaccines co-
hort, parallel testing with rapid diagnostic tests (RDTs) was
performed (SD Bioline HIV-1/2 3.0 [Standard Diagnostics,
Gyeonggi-do, Republic of Korea] and Determine HIV-1/2
[Alere Medical, Waltham, Massachusetts]); discordant results
were conﬁrmed by ELISA (Vironosticka Uniform II plus O
and Murex HIV 1.2); discordant EIA results were conﬁrmed
by Western blot (INNO-LIA; Innogenetics, Ghent, Belgium)
[37].The Uganda GoodHealth forWomen project tested women
using a single Determine rapid diagnostic test (Abbott Determine
HIV-1/2) with conﬁrmation of positive results using parallel
ELISAs (Vironosticka Uni-Form II plus O, Murex HIV 1.2.O).
Discordant results were conﬁrmed by Western blot (Cambridge
Calypte, Portland, Oregon) [35].
Serological tests for syphilis were analyzed by a rapid plasma
regain (RPR) test (Biotec, Birdport, UK) and the Treponema
pallidum hemagglutination (TPHA) test (Biotec). Results from
both tests were used to deﬁne active syphilis (positive results of
both tests), past or treated syphilis (a negative result of the RPR test
and a positive result of the TPHA test), and negative for syphilis
(negative results of both tests or a positive result of the RPR test
and a negative result of the TPHA test) in all but 1 study. One
study only performed the TPHA test if participants had a positive
result of the RPR test. All studies tested serum samples for antibod-
ies to herpes simplex virus type 2 (HSV-2), using a type-speciﬁc
immunoglobulin ELISA (Kalon Biologicals, Guildford, UK).
Cervical swabs were tested by polymerase chain reaction
analysis for Neisseria gonorrhoeae and Chlamydia trachomatis
(Amplicor; Roche). Vaginal swabs were used to culture Tricho-
monas vaginalis, using In-Pouch (Biomed Diagnostics, White
City, Oregon), and to prepare a Gram-stained slide for the
detection of bacterial vaginosis, using the Nugent score.
Statistical Methods
Conditional logistic regression was used to analyze associations
between HIV acquisition and (1) the presence of an HPV geno-
type–speciﬁc infection at the visit prior to the HIV serocon-
version visit (the s − 1 visit), or at the equivalent visit in
controls, (2) evidence of any HPV clearance, persistent HPV in-
fection only, or HPV acquisition only. Clearance was deﬁned as a
genotype-speciﬁc positive test result followed by a negative test
result for the same genotype, regardless of the status of other
HPV coinfections. Persistence was deﬁned as detectable infection
with the same genotype for ≥6 months with no evidence of clear-
ance of other genotypes. Acquisition was deﬁned as a negative
HPV test result followed by a positive HPV test result for the
same genotype and no evidence of clearance or persistence of
other genotypes. The possible combinations of visits attended by
the cases and controls selected for this study and visit classiﬁca-
tions are detailed in Figure 1. Owing to variations in question-
naires, a number of variables identiﬁed a priori as potential
confounders were recoded to be consistent across studies (Table 2).
First, age-adjusted analyses, with age as a categorical variable,
were performed on all available covariates identiﬁed a priori as
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potential confounders and common to all study questionnaires, to
assess their association with HIV acquisition (Table 2). Informa-
tion on sociodemographic and behavioral covariates was either
from baseline (the enrollment questionnaire) or time-updated
to values at the time of ﬁrst detection of HIV seroconversion
(the index visit; s0). Since STI data were not gathered at every
visit, time-updated STI results used data from both the s0 visit
and the s − 1 visit; women were classiﬁed as positive for the
STI if they had a positive test result at either time point.
Next, age-adjusted analyses of the association of HPV with
HIV acquisition were performed. Multivariable models to con-
trol for potential confounding were then constructed. Variables
describing mobility, vaginal cleansing practices, Trichomonas
infection, and presence of genital warts were not included in
the multivariable analysis because of missing data. The remain-
ing covariates were assessed iteratively for evidence of a change
in the effect estimate for the association of HPV and HIV, start-
ing with covariates with the strongest association with HIV in
age-adjusted analyses. To minimize the number of parameters
estimated in the model, only covariates that inﬂuenced the
size of the effect estimate for HPV remained in the multivariate
model. Multicollinearity was assessed against a model ad-
justed only for age. All P values were generated by likelihood
ratio tests. Assuming an HPV prevalence of 30%–50% in con-
trol subjects, 150 HIV-positive cases and 450 HIV-negative
controls, we calculated that we would have ≥80% power to de-
tect an odds ratio (OR) of ≥1.75 for the association between
HIV acquisition and HPV infection at the visit before HIV
seroconversion.
RESULTS
Across all time points, 90 of the 1258 samples (7%) returned an
invalid/inhibited HPV result on ﬁrst testing. Sixty-six of these
samples had sufﬁcient volume to be retested; 41 gave a valid
HPV result. Valid HPV results were therefore available for
1209 samples (96%). At the s − 1 time point, 625 of 664
women (94%; 161 cases and 464 controls) returned valid
HPV test results and therefore contributed to the main analysis
of the association between HIV status and HPV prevalence.
The mean age of cases and controls at enrollment was 25 years
(range 16–45 years; Table 2). One ﬁfth of women (22%) were
married or living as married. Over 50% of women stated that
their main source of income came from restaurant or bar or
guesthouse work and 24% identiﬁed themselves as local brew
or street food sellers. A proportion of those whose income source
was categorized as “other”may have been sex workers, as this was
only determined as a separate category in the Ugandan study. Al-
though 49% had completed primary education, <18% had some
secondary or higher education. In time-updated data from the
visit of ﬁrst detection of HIV (s0) approximately one third of
women reported not currently using any form of contraception,
whereas 57% reported having used a condom at last sex.
Younger age was strongly associated with HIV seroconversion
(Ptrend < .001; Table 2). In age-adjusted analysis, women report-
ing a higher number of lifetime partners, having been paid for sex
in the past 3 months, and those drinking alcohol more frequently,
had a signiﬁcantly increased odds of HIV seroconversion.
Women who had completed primary education had a higher
risk than those with incomplete primary education. Women
who experienced forced sex during the 3 months prior to enroll-
ment had a higher risk of HIV seroconversion, but this effect was
not statistically signiﬁcant. At the s0 or the s− 1 visit, 10% of
cases and controls had C. trachomatis infection, 11% had N. gon-
orrhoeae infection, and 86% had evidence of exposure to HSV-2.
These infections signiﬁcantly increased the odds of HIV serocon-
version by 2.8-, 2.6-, and 2.0-fold, respectively (Table 2).
HPV Prevalence Before HIV Acquisition
The median interval between the s− 1 visit and the ﬁrst visit at
which HIV was detected (the s0 visit) was 3 months; 87% of
cases and controls had a cervical sample at or <6 months
prior to the s0 visit.
At the s− 1 visit, 49% of women (51.6% of cases and 48.5% of
controls) across groups A–D in Figure 1 had detectable HPV
infection of any genotype. In adjusted analyses, there was no ev-
idence that prevalent infection with any HPV genotype at the
visit prior to the ﬁrst detection of HIV was associated with
HIV acquisition (adjusted OR for any HPV type infection,
1.02; 95% CI, .66–1.57; Table 3).
Figure 1. Combinations of original study visits and available human papillomavi-
rus (HPV) test results, relative to the visit at which human immunodeficiency virus
(HIV) was first detected, attended by cases and controls and selected for analysis.
The s− 1 visit denotes the visit preceding the visit during which HIV seroconversion
was detected, and the s− 2 visit denotes the visit preceding the s− 1 visit.
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Table 2. Characteristics of the Matched Cases and Controls and Age-Adjusted Associations With Case-Control Status, Using Conditional Logistic
Regression
Characteristic Cases, No. (%) (n = 161) Controls, No. (%) (n = 464) Age-Adjusted OR (95% CI) P Value
Enrollment data
Age group, y
16–24 79 (49.0) 178 (38.4) 1 <.001a
25–34 70 (43.5) 208 (44.8) 0.64 (.41–.99)
≥35 12 (7.5) 78 (16.8) 0.28 (.13–.57)
Marital status
Married/living as married 27 (16.8) 109 (23.5) 1 .221
Separated/divorced/widowed 94 (58.4) 252 (54.3) 1.54 (.92–2.57)
Single 40 (24.8) 103 (22.2) 1.22 (.66–2.25)
Religion
Christian 121 (75.2) 326 (70.3) 1 .495
Muslim 34 (21.1) 121 (26.1) 0.78 (.49–1.23)
Other/no religion 6 (3.7) 17 (3.6) 1.21 (.46–3.19)
Main occupation
Restaurant/bar worker/cleaner 85 (52.8) 247 (53.2) 1 .916
Local brew or street food vendor 40 (24.8) 113 (24.4) 1.05 (.64–1.74)
Manager/owner/office worker 8 (5.0) 34 (7.3) 0.79 (.33–1.89)
Sex workerb 18 (11.2) 46 (9.9) 1.22 (.59–2.53)
None/other 10 (6.2) 24 (5.2) 1.26 (.56–2.80)
Maximum education level
None/incomplete primary 48 (29.8) 162 (34.9) 1 .008
Complete primary 92 (57.1) 214 (46.1) 1.61 (1.04–2.51)
Some secondary/higher 21 (13.0) 88 (19.0) 0.66 (.36–1.23)
Crowdingc
0–2 95 (56.9) 248 (50.5) 1 .116a
3–4 45 (27.0) 129 (26.3) 0.64 (.41–.99)
≥5 27 (16.2) 114 (23.2) 0.29 (.14–.59)
Lifetime no. of sex partnersd
<5 50 (31.9) 179 (39.5) 1 .024a
5–9 39 (24.8) 92 (20.3) 1.71 (1.02–2.87)
≥10 24 (15.3) 80 (17.7) 1.49 (.81–2.75)
Do not remember 44 (28.1) 102 (22.5) 2.78 (1.33–5.82)
Forced sexe
No 121 (77.1) 378 (83.1) 1 .058
Yes 36 (22.9) 77 (16.9) 1.79 (.98–3.23)
Alcohol consumption
Never 53 (32.9) 193 (41.6) 1 .003a
1 time/wk or less 9 (5.6) 52 (11.2) 0.60 (.28–1.32)
2–3 times/wk 47 (29.2) 114 (24.6) 1.75 (1.06–2.91)
≥4 times/wk 52 (32.3) 105 (22.6) 2.02 (1.23–3.33)
Time-updated data
Current method of family planningf
Nothing 50 (31.1) 143 (31.4) 1 .650
Oral pill 29 (18.0) 84 (18.5) 1.04 (.58–1.86)
Injection 45 (28.0) 100 (22.0) 1.30 (.77–2.17)
Condom 30 (18.6) 103 (22.6) 0.83 (.48–1.43)
Other (eg, traditional/calendar) 7 (4.4) 25 (5.5) 0.93 (.34–2.57)
Condom use at last sexg
No 87 (55.4) 268 (60.1) 1 .439
Yes 70 (44.6) 178 (39.9) 1.16 (.79–1.71)
Transactional sexh
No 85 (53.1) 290 (63.7) 1 .002
Yes 75 (46.9) 165 (36.3) 2.18 (.37–.98)
Partners in the last 3 mo
None/1 94 (58.8) 298 (65.5) 1 .148a
2–9 39 (24.4) 89 (19.6) 1.50 (.91–2.47)
≥10 18 (11.3) 54 (11.9) 1.30 (.58–2.93)
Do not remember 9 (5.6) 14 (3.1) 2.52 (.90–7.00)
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Additional analyses of HR-HPV and LR-HPV types, analyses
of nonavalent vaccine types (Table 3), and analyses restricted to
the 87% of participants with s− 1 samples collected ≤6 months
before HIV seroconversion (Supplementary Table 2) did not
show notably different results.
HPV Clearance or Persistence and HIV Acquisition
A total of 119 cases and 323 controls had data from at least 2
time points (groups B–D in Figure 1) and were included in the
analysis of the association of HPV clearance and/or persis-
tence with HIV acquisition. Among these women, 42% had
evidence of clearance of an HPV genotype irrespective of
the status of other genotype-speciﬁc infections (the “any
clearance” group), 10% had evidence of 6-month persistence
with an HPV genotype only (with no evidence of clearance,
with/without acquisition of a different genotype), and 13%
had evidence of acquisition of an HPV genotype only (with
Table 2 continued.
Characteristic Cases, No. (%) (n = 161) Controls, No. (%) (n = 464) Age-Adjusted OR (95% CI) P Value
STI test results at the s0 and s− 1 visits
C. trachomatis
Negative at both visits 133 (82.6) 431 (92.9) 1 <.001
Positive at ≥1 visit 28 (17.4) 33 (7.1) 2.76 (1.57–4.87)
N. gonorrhoeae
Negative at both visits 130 (80.8) 426 (91.8) 1 <.001
Positive at ≥1 visit 31 (19.3) 38 (8.2) 2.58 (1.51–4.41)
HSV-2i
Negative at both visits 15 (9.4) 70 (15.2) 1 .022
Positive at ≥1 visit 144 (90.6) 392 (84.9) 2.00 (1.08–3.75)
Abbreviations: CI, confidence interval; C. trachomatis, Chlamydia trachomatis; HSV-2, herpes simplex virus type 2; N. gonorrhoeae, Neisseria gonorrhoeae; OR, odds ratio; s0 visit, the visit
during which HIV seroconversion was detected; s− 1 visit, the visit preceding the visit during which HIV seroconversion was detected STI, sexually transmitted infection.
a For linear trend. In the association with number of partners, we assume that women who stated “do not remember” had the highest number of partners.
b Only the Ugandan study included sex work as a category in answer to the question “What is your main source of income?”
c Data are no. of people living in the participant’s residence.
d Data for 15 women (11 [2.4%] of controls and 4 [2.5%] of cases) were missing.
e Data are for experience of forced sex during the 3 mo before enrollment. Data for 13 women (9 [1.9%] of controls and 4 [2.5%] of cases) were missing.
f Data for 9 women (1.9% controls) were missing.
g Data for 22 women (18 [3.8%] of controls and 4 [2.5%] of cases) were missing.
h Data are for experience of transactional sex during the 3 mo before enrollment. Data for 10 women (1 case [<1%] and 9 controls [2%]) were missing.
i Data for 4 women (2 cases [1%] and 2 controls [<1%]) were missing.
Table 3. Associations Between Human Papillomavirus (HPV) Infection at the Visit Preceding the First Detection of Human Immunodeficiency Virus (HIV)
Seroconversion (the s− 1 Visit) and Subsequent HIV Acquisition Among Women With a Valid HPV Test Result at the s− 1 Visit
HPV Infection Status
at s − 1
Cases, No. (%)
(n = 161)
Controls, No. (%)
(n = 464)
Age-Adjusted Analysis Adjusted Analysis 1a Adjusted Analysis 2b
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Any type
No infection 78 (48.5) 239 (51.5) 1 .783 1 .923 1 .926
Any HPV infection 83 (51.6) 225 (48.5) 1.06 (.72–1.56) 1.02 (.68–1.53) 1.02 (.66–1.57)
Nonavalent vaccine types
No HPV infection 78 (48.5) 239 (51.5) 1 .867 1 .875 1 .901
Nonavalent vaccine–type
HPV infection
38 (23.6) 103 (22.2) 0.99 (.61–1.60) 0.95 (.57–1.56) 0.95 (.56–1.61)
Other HPV infection 45 (28.0) 122 (26.3) 1.12 (.71–1.75) 1.09 (.68–1.75) 1.08 (.66–1.78)
HR/LR-HPV infection
No HPV infection 78 (48.5) 239 (51.5) 1 .667 1 .738 1 .658
HR-HPV infection only 27 (16.8) 70 (15.1) 1.08 (.63–1.85) 1.07 (.60–1.89) 1.15 (.63–2.08)
LR-HPV infection only 33 (20.5) 83 (17.9) 1.26 (.75–2.12) 1.19 (.69–2.06) 1.17 (.66–2.08)
HR/LR-HPV coinfection 23 (14.3) 72 (15.5) 0.85 (.48–1.48) 0.82 (.45–1.47) 0.78 (.43–1.44)
Abbreviations: CI, confidence interval; HR, high risk; LR, low risk; OR, odds ratio.
a Data are from 160 cases and 455 controls with available data and were adjusted for variables that influenced the effect estimate of the association between any HPV at s1 and HIV (ie, age
group, alcohol consumption at enrollment, and transactional sex in the 3 months prior to first detection of HIV [time-updated variable]).
b Data are from 158 cases and 454 controls with available data and were adjusted for the same variables as for adjusted analysis 1, as well as for the time-updated sexually transmitted infection
variables Chlamydia trachomatis detection, Neisseria gonorrhea detection, and herpes simplex virus type 2 (HSV-2) detection. Women were classified as positive for C. trachomatis, N.
gonorrhea, or HSV-2 if they had results for tests performed at the s0 and/or s− 1 visits and if the result from at least 1 visit was positive.
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no concurrent clearance or persistence; Table 4). Among the
237 women with HPV data from an s − 2 visit, 94% had a s − 2
cervical sample collected at or within 12 months prior to the
s0 visit.
Adjusted analyses based on data from all available time points
did not show evidence of an association between the clearance,
persistence, or acquisition of HPV infection and HIV acquisition
(Table 4). Additional analyses restricted to s− 2 and s− 1 time
points and excluding data from the s0 visit, when HIV infection
could have inﬂuenced HPV infection, yielded somewhat larger
effect estimates for all associations between HPV and HIV. How-
ever, CIs were wide, and none of the results were statistically sig-
niﬁcant (Supplementary Table 3).
DISCUSSION
In these cohorts of Tanzanian and Ugandan women, there was
no evidence of an association between HPV infection, clearance,
persistence, or acquisition and the odds of HIV acquisition.
These results stand in contrast to other observational studies in
high-risk women, which found a 2-fold increased risk of HIV ac-
quisition in those who were HPV positive [23]. There is a plau-
sible mechanism by which HPV infection could increase the risk
of HIV acquisition throughmechanical or immunological chang-
es in the cervix [20–22]. There is strong evidence of cofactor ef-
fects of other STIs on HIV transmission [39–46]. We sought to
conﬁrm the ﬁndings of previous studies and add to limited data
on HPV clearance and subsequent HIV acquisition, but we were
unable to provide evidence in our study populations for such
association.
Strengths of our study include its size; with 161 cases and 464
controls, our study is the largest to date. In previous studies, the
number of HIV seroconverters ranged from 4 to 145 women
[24–26, 28, 47]. The original cohort studies used for our inves-
tigation had high retention rates, and the characteristics of cases
and controls were very similar. Cases and controls were selected
from the same populations and matched to account for different
study sites and designs and for individuals’ adherence to study
procedures. A sensitivity analysis showed that results did not
differ between studies using cervical swab specimens and the
one study using CVL specimens to diagnose HPV infection.
The risk of misclassiﬁcation of HIV infection status was low,
as all studies used conﬁrmatory HIV tests.
There are a number of possible reasons why our results differ
from those reported in the literature. Apart from the Ugandan
women, who included self-identiﬁed sex workers, it could be
considered that the remainder of the participants had a lower
risk of HIV acquisition than women recruited in previous stud-
ies, some of which only recruited sex workers [24, 26].However,
>80% of both cases and controls in our study were HSV-2 sero-
positive. Although cases in previous studies had a similarly high
HSV-2 prevalence, the prevalence in controls was signiﬁcantly
lower in previous studies [27, 47]. Interactions between HPV,
other sexually transmitted pathogens, and the cervical-vaginal
microbiome are unclear; however, the effect of STIs on HIV ac-
quisition may diminish the relative effect of HPV. External
quality control results from the ICO laboratory indicated fair
agreement in the detection of HPV genotypes; nondifferential
misclassiﬁcation of HPV infection may have diluted the mea-
sured effect of HPV on HIV.
Across all exposure variables investigated, there was little ev-
idence of confounding. No information on the relative risk sta-
tus of the participants’ sex partners was available and missing
data precluded controlling for T. vaginalis infection, mobility,
vaginal cleansing practices, and the presence of genital warts.
Table 4. Associations of Human Papillomavirus (HPV) Persistence, Clearance, and Acquisition With Subsequent Human Immunodeficiency Virus (HIV)
Infection Among Women Who Had Valid HPV Test Results From at Least 2 Time Points
HPV Persistence, Clearance,
Acquisition Prior to
HIV Seroconversiona
Cases,
No. (%)
(n = 119)
Controls,
No. (%)
(n = 323)
Age-Adjusted Analysis Adjusted Analysis 1b Adjusted Analysis 2c
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Among all women with >1 valid result (at s0, s − 1, or s− 2)
Uninfected 37 (31.1) 118 (36.5) 1 .771 1 0.765 1 .685
Any HPV clearance 53 (44.5) 134 (41.5) 1.17 (.68–2.00) 1.08 (.61–1.89) 0.85 (.46–1.55)
HPV persistence for 6 mo 10 (8.4) 33 (10.2) 0.97 (.41–2.28) 0.94 (.39–2.27) 0.93 (.37–2.29)
HPV acquisition only 19 (16.0) 38 (11.8) 1.42 (.68–2.95) 1.44 (.68–3.04) 1.33 (.61–2.90)
Abbreviations: CI, confidence interval; OR, odds ratio.
a Women who remained HPV negative at all available time points were classified as uninfected. Women with evidence of any HPV clearance, defined as a genotype-specific positive test result
followed by a genotype-specific negative result, regardless of concurrent HPV persistence or acquisition, were classified as having any HPV clearance. Women with at least 2 genotype-specific
positive test results at least 6 mo apart, with or without evidence of acquisition of other genotypes, were classified as having HPV persistence for 6 mo. Women who only had a genotype-
specific negative test result followed by a positive result for the same genotype at a later time point, with no evidence of persistence or clearance of other genotypes, were classified as having
HPV acquisition only.
b Data are for 118 cases and 319 controls with available data and are adjusted for age group, alcohol consumption at enrollment as a linear variable, and transactional sex in the 3 months before
the visit when HIV was first detected (ie, the same model as used for the analysis of the effect of prevalent HPV in Table 3; all other covariates were checked, but no other residual confounding
was found).
c Data are for 117 cases and 319 controls with available data and are adjusted for age, alcohol consumption at enrollment as a linear variable, transactional sex, and Chlamydia trachomatis and
herpes simplex virus type 2 detection at time of or the visit before the first visit when HIV was detected. Neisseria gonorrhea detection was removed from the model to reduce the number of
parameters, as it did not affect the adjusted OR.
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However, when analyzing the available data on these variables,
there were no signiﬁcant associations with HIV status. Cases
and controls were well balanced with regard to baseline STIs;
however, residual confounding related to differences in sexual
behavior cannot be excluded. The numbers of participants
with clearance and 6-month persistence were small, and CIs
were wide; the existence of a moderate effect of HPV on HIV
acquisition cannot be ruled out.
Our study used samples that had been stored in freezers for
3–9 years. Samples that have been embedded in parafﬁn show
good reproducibility [48, 49]; however, the durability of DNA
in frozen swab aliquots or CVL specimens after long-term
storage is undocumented. There is some evidence that de-
tection of β-globin decreases over time, leading to a greater
number of faint/invalid results and, therefore, potential mis-
classiﬁcation of HPV infection status. The inclusion of s0 sam-
ples in our analysis could limit the temporal relevance of the
analysis of clearance and persistence. Acquisition of HIV be-
tween the s − 1 and s0 time points may have increased the
probability of HPV persistence and/or new acquisition of
HPV, which was then detectable at the s0 time point [17].
However, these time points have been used in the 2 previous
studies analyzing the effect of HPV clearance and persistence
on HIV, with a similar prevalence of clearance (around 40%)
[27, 28]. When restricting our analysis to the s − 2 and s − 1
time points, the effect estimates were larger; however, CIs
were wide, and P values preclude any clear conclusions. All
studies of the association between HPV and HIV infection po-
tentially suffer from inadequate methods of deﬁning HPV in-
fection status. More research is needed to ﬁnd biological
markers of newly acquired infection, latent infection, clear-
ance, and persistence.
In conclusion, the HIV epidemic remains a serious problem
in sub-Saharan Africa, which simultaneously harbors the high-
est burden of HPV infection in the world [4]. If previous reports
are accurate and HPV infection leads to a 2-fold increase in risk
of HIV acquisition, the highly effective HPV vaccines could
substantially inﬂuence rates of HIV acquisition in areas of
high HPV incidence. Whereas previous studies suggested that
HPV infection enhances the risk of HIV acquisition, our study,
based on a large data set from 5 cohorts in East Africa, could not
conﬁrm this association; more research is needed to clarify
these contrasting results. Given the contradictory evidence of
an association between HPV and HIV, a cluster randomized
controlled trial of phased delivery of HPV vaccine with moni-
tored HIV infection incidence may be the only way of con-
cluding whether there is a causal relationship between HPV
infection and HIV acquisition.
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